$4.83
1.26% yesterday
NYSE, Nov 14, 10:00 pm CET
ISIN
US20454B1044
Symbol
CMPX

Compass Therapeutics Stock price

$4.83
+0.49 11.29% 1M
+2.83 141.50% 6M
+3.38 233.10% YTD
+3.24 203.77% 1Y
+0.14 2.99% 3Y
-3.67 43.18% 5Y
-3.67 43.18% 10Y
-1.42 22.72% 20Y
NYSE, Closing price Fri, Nov 14 2025
+0.06 1.26%
ISIN
US20454B1044
Symbol
CMPX
Industry

Key metrics

Basic
Market capitalization
$859.1m
Enterprise Value
$639.2m
Net debt
positive
Cash
$219.9m
Shares outstanding
177.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.1
Financial Health
Equity Ratio
89.2%
Return on Equity
-39.4%
ROCE
-24.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-52.2m | $-85.8m
EBIT
$-53.5m | $-82.7m
Net Income
$-49.2m | $-97.9m
Free Cash Flow
$-45.1m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
4.8% | -53.1%
EBIT
3.6% | -46.1%
Net Income
-3.0% | -98.3%
Free Cash Flow
6.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
14.8%
Employees
35
Rev per Employee
$20.0k
Show more

Is Compass Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

Compass Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Compass Therapeutics forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Compass Therapeutics forecast:

Buy
94%
Hold
6%

Financial data from Compass Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
23% 23%
-
- Research and Development Expense 42 42
1% 1%
-
-52 -52
5% 5%
-
- Depreciation and Amortization 1.24 1.24
103% 103%
-
EBIT (Operating Income) EBIT -53 -53
4% 4%
-
Net Profit -49 -49
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Compass Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Compass Therapeutics Stock News

Neutral
GlobeNewsWire
10 days ago
Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026. A new response in a third indication has been observed in the fifth and final dosing cohort of...
Neutral
GlobeNewsWire
11 days ago
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.
Neutral
GlobeNewsWire
12 days ago
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November. Details are as follows: Guggenheim 2nd An...
More Compass Therapeutics News

Company Profile

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Head office United States
CEO Thomas Schuetz
Employees 35
Founded 2014
Website www.compasstherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today